Table 2 Summary of adverse events (no. (%)) in patients with osteoarthritis who received risedronate or placebo
Placebo | Risedronate | ||
|---|---|---|---|
(n = 98) | 5 mg/day (n = 96) | 15 mg/day (n = 90) | |
Patients with AEs | 94 (96%) | 95 (99%) | 84 (93%) |
Dropouts due to AEs | 12 (12%) | 7 (7%) | 10 (11%) |
Overall GI AEs | 15 (15%) | 16 (17%) | 7 (8%) |
Abdominal pain | 6 (6%) | 7 (7%) | 3 (3%) |
Dyspepsia | 7 (7%) | 7 (7%) | 3 (3%) |
Gl disorder | 3 (3%) | 1 (1%) | 1 (1%) |